



Transforming Food Allergy Treatment
Via a Novel Immunotherapy Platform

Our Goal Is to Transform How Food Allergies Are Managed

We are developing a **novel immunotherapy platform** with **multiple food allergy applications** that reinvents how allergies are managed.

We will transform lives by addressing the unmet needs of people living with food allergies through development of solutions that optimize **safety, efficacy and adherence.**



Our first application targets the >\$7 billion peanut allergy market

Executive Summary



Problem

- **Large, growing market:**
>220 million people globally with food allergies; 32 million in U.S.
- **Significant unmet need:**
Causes severe health events & lifestyle impacts, with no cure
- **Suboptimal treatment options:**
Current solution doesn't deliver robust safety, efficacy & adherence profile



Our Solution

- **Novel, simplified approach:**
Oral Mucosal Immunotherapy (OMIT) for food allergy desensitization
- **Significant differentiation:**
Dramatically reduced risk profile vs OIT*; built-in adherence via toothpaste delivery
- **Positive Phase 1 / 2 study results:**
Indicate platform is safe; Reactions to peanut exposure appear to decrease over time – potential desensitization



Opportunity



- **Multi-billion \$ market:**
First application targets peanut allergies; ~\$7B TAM in U.S. alone
- **Opportunity with reduced risk and high expected ROI:**
Safety established; product development advanced; strong IP
- **Minimal competition:**
Only one peanut allergy product approved – it is significantly challenged

Intromune is currently seeking \$35 million in Series B funding

Large & Growing Global Problem



Food allergies have become a serious public health concern as prevalence increases globally



Peanut
(18%)

Peanut Allergy

\$7.4 Billion

TAM for U.S. market only³

Significant Medical & Lifestyle Impacts



SEVERE HEALTH EVENTS

40-50%+

of people with food allergies have experienced a severe allergic reaction^{*1}



MEDICAL CARE

200,000

Americans require emergency medical care each year for allergic reactions to food¹



FEAR

92%

of parents feel fearful for their child's safety because of food allergies²



SOCIAL EXCLUSION

5 in 10

families with food allergies skip out on important school functions²



DISRUPTION

44%

of parents had to make a career change to care for their child with food allergies²



COST

\$25 Billion

spent annually by U.S. families caring for children with food allergies¹

No Cure & Current Solutions Are Lacking

LIFESTYLE SOLUTIONS

- Avoidance of problem foods
- Learn to recognize and treat reaction symptoms (e.g. EpiPen®)



IMMUNOTHERAPY SOLUTIONS

- Only one product ever approved for food allergy (Palforzia® for peanuts)
- Does not fully deliver on safety, ease of adoption & adherence:

Safety

- ~9.5% experienced anaphylaxis, which may be life-threatening¹
- 14% use of epinephrine reported in one Phase 3 pivotal trial¹
- >35% experienced moderate* treatment-related adverse events²


Adoption Barriers

- Requires frequent visits to allergy clinic every 2 weeks for ~6 months
- 5-hour initial office visit; issue given lack of physician compensation
- Discontinuation rate of ~22%¹

Our Solution: Complex Biochemistry Simplified via Novel Administration


Complex patented biochemistry transformed into novel, easy-to-use immunotherapy platform: Oral Mucosal Immunotherapy (OMIT)

1




Peanut allergenic proteins (API)
mechanically & chemically
extracted via proprietary methods

2




API stabilized & embedded
in functional toothpaste
in metered-dose dispenser

3



Immunotherapy
conveniently administered
with daily teeth brushing

4



Novel OMIT pathway leverages
Langerhans cells in entire oral cavity
to reeducate immune system,
desensitizing users to allergens

How Oral Mucosal Immunotherapy Works


1

Proprietary formula delivers allergenic protein to oral cavity via toothpaste, binding to mucosa




2

Langerhans cells pull allergenic protein into the lymph system




3

Langerhans cells trigger the reeducation of immune system



4

Differentiated T cells decrease the allergic response



Our Patented OMIT Solution Delivers Highly Differentiated Benefits



Safe, effective, easy-to-use solution delivers reduced risk profile



Efficacious

- Research studies have shown food proteins in oral cavity can desensitize patients
- Maximizes oral absorption – 16x oral Langerhans cells*




Significantly Reduced Risk Profile

- API is expelled after brushing; reduced risk of systemic reactions and GI distress



Safe

- Phase 1 / 2 study indicates the platform is safe
- Avoids GI system – absorbed in mouth (via lymph system) then spat out



Lower Adoption Barriers

- Fewer, shorter up-dosing office visits required
- Efficient dosing – targeting faster time to reach maintenance and efficacy



High Adherence

- Toothpaste deliver provides built-in adherence – integrated into daily behavior
- Opportunity to be “maintenance product of choice”

INT301 Designed from the beginning to address the limitations of OIT



Intrimmune's safe, effective, easy-to-use solution addresses barriers with competitive offering

	PALFORZIA®	Intrimmune INT301
Simplicity	<ul style="list-style-type: none">• Inconvenient delivery may impact long-term adherence• Patients must add peanut powder to semi-solid food daily	<ul style="list-style-type: none">• Simple toothpaste delivery format fits conveniently into existing daily routine, for embedded adherence• 98% reported adherence & 0% drop-out* in study
Safety	<ul style="list-style-type: none">• Significant risk profile<ul style="list-style-type: none">- Increased systemic allergic reactions- Increased discontinuation due to AEs (GI Pain)- Increased reports of EoE**• Higher rate of anaphylaxis (14%); increased risk of ER visit	<ul style="list-style-type: none">• Significantly reduced risk profile<ul style="list-style-type: none">- API is expelled after brushing, reducing risk of systemic reactions and GI distress- Transient, local AEs with no serious events reported, no anaphylaxis or use of emergency epinephrine
Adoption Barriers	<ul style="list-style-type: none">• Requires frequent visits to allergy clinic every two weeks for about six months• Lengthy (4-5 hour) first office visit• Restrictive REMS (Risk Evaluation and Mitigation Strategy)• Patients still complain of peanut taste• Launched during COVID	<ul style="list-style-type: none">• Expected to require fewer office visits• Typical (~1 hour) first office visit, one tooth brushing• Planning to leverage impressive safety data to try to mitigate need for REMS• Differentiated API processing significantly reduces peanut taste + toothpaste is flavored

First Application Is Peanut Allergy Market – A Leading Food Allergen



OPPORTUNITY

TAM

\$7.4 Billion
(U.S. market only)

GROWTH

Market forecasted to grow
1,700-fold
from 2017 to 2027¹

INSURANCE COVERAGE

Yes

OUT PRICE/YEAR PER PATIENT

\$10,680

LARGE & GROWING UNMET NEED



6M

U.S. Peanut
Allergic Pop



1.6M

U.S. Peanut
Allergic Children



1M

Diagnosed
(Aged 4 – 18 years)



690K

Immediate
serviceable market
for Intromune*

Development Substantially De-Risked for Peanut Allergy Solution



Significant progress made to de-risk development

Product Development

- Process established for extracting peanut allergen protein
- Method created for stabilizing protein in functional toothpaste
- Packaging developed: pump dispenser



Regulatory

- Clear approval pathway identified
- IND filed & accepted; highly collaborative FDA review
- Faster path to market: No toxicology, pharmacokinetics or animal models required



Clinical

- Last Patient Last Visit (LPLV) June 30, 2023
- Data unblinding early-August, 2023
- Statistical analysis mid-August 2023
- CSR September 2023
- Due to impressive safety profile to date, FDA greenlit our pediatric Phase 2 study prior to completion of our adult Phase 1 / 2 study

Encouraging Results As LPLV Completed in Phase 1 / 2 OMEGA Study



Blinded results at LPLV may provide insights on safety, efficacy, adherence



Efficacy

Reactions due to peanut exposure appear to decrease over time – indicating potential efficacy (unblinded data available after mid-August under NDA)



Safety

No severe Adverse Events, no anaphylaxis and no use of emergency epinephrine. All AEs transient in nature (n=32)



Adherence

98+% adherence to daily toothbrushing requirement (patient-reported)




Dropout

0% product-related patient dropout rate

Series B Funding Will Cover Phase 2 Pediatric Study



Intrommune Therapeutics INT301 Clinical Timeline



Series B Funding Requirements



\$35 million in funding for Phase 2 pediatric study

Series A/Bridge - \$10 Million (closed)

Accomplished

- Exclusive global rights to OMIT for food allergy
- INT301 formulation developed
- IND accepted
- Completed Phase 1 / 2 (Adults)

Investors



Chemical Angel Network

Series B - \$35 Million

Goals

- Complete Phase 2 study in pediatrics
- Prepare CMC processes
- Product development to expand to new applications
- Identify strategic and market opportunities
- Shape market & establish brand prior to launch

Extensive Global IP Protection

IP covers all food allergens across multiple oral care formats, with 47 patents to date



EXCLUSIVE GLOBAL IP

- For all food allergy immunotherapy
- Freedom to operate



GLOBAL PORTFOLIO

- United States
- European Union
- China
- India
- Japan



TWO PATENT FAMILIES

- Immunotherapy via multiple oral care formats
- Formulations to stabilize allergens



GLOBAL PROTECTION

- Expected to extend to 2044



ADDITIONAL IP EXPECTED

- Additional innovation
- New filings - Dosing, CMC & design
- Regulatory extension
- Unique biologic – no generic pathway available

Experienced Leadership Team

Experience successfully bringing innovation to market, including in biotech, pharma and allergy markets:



Michael Nelson, JD
Chief Executive Officer



Stuart Loesch
President / Chief Commercial Officer



Alain Van Loo
Chief Operating Officer



Nandini Murthy
Head of Regulatory



William Berger, MD, MBA
Head of Medical Affairs



Wendy Perrow, MBA
Head of Innovation



Christopher Schuster, MBA
Chief Financial Officer

High Expected ROI for Intrimmune Opportunity



Low risk allergy immunotherapy targeting an established, reimbursed market

- ✓ **Large, growing market** with established reimbursement
 - Significant unmet need
 - Peanut allergy TAM of ~\$7B in U.S. alone
- ✓ **Multiple applications & opportunities** enabled by unique immunotherapy platform technology
- ✓ **Minimal competition** - Only one peanut allergy product ever approved for any food allergy
- ✓ **OMIT highly differentiated** vs. current OIT solution, with expected safety, efficacy & adherence benefits:
 - Intrimmune's Peanut INT301 is best-in-class agent – 9 in 10 subjects¹ will use
 - Opportunity to position as “maintenance product of choice” for those started on other immunotherapies

Disclosures



Important Information

The information regarding the proposed private placement offering by Intromune Therapeutics is being provided to you on a confidential basis only and should not be disclosed to anyone other than your professional advisers on a confidential basis for purposes related to your interest in the company. This information should not be divulged, reproduced or disseminated without our consent.

Only qualified “accredited investors” as defined in Regulation D under the Securities Act of 1933, as amended will be permitted to participate in the proposed offering. Additional suitability requirements may apply.

These materials do not constitute either an offer to sell or an offer to purchase securities. Any purchase of securities will be made pursuant to and governed by a subscription agreement between the company and the investor, and the company will have the right to accept or reject subscriptions in its sole discretion. There is no minimum amount of subscriptions we must receive before we close on any subscription.

We will make available to any prospective purchaser and such person’s advisers the opportunity to ask questions and receive answers concerning the terms and conditions of the proposed offering, the company, or any other relevant matters, and to obtain any additional information to the extent the company possesses such information.

Any investment in Intromune Therapeutics involves a high degree of risk. You should carefully read all of the risk factors attached to the subscription agreement prior to any investment. There is no assurance that an investment will be profitable at any time.

Neither Intromune Therapeutics nor any of its equity interests are registered with the Securities and Exchange Commission or the securities regulator of any state.

This communication contains forward-looking statements, which can be identified by, among other things, the use of forward-looking language, such as the words “plans,” “intends,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “potential,” “may,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” or other similar words, or by discussion of strategy or intentions. Forward-looking statements are based upon management’s present expectations or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. The information contained herein and in the documents enclosed herewith is current only as of the date hereof and you should not, under any circumstances, assume that there has not been any change in the matters discussed herein or in the documents enclosed herewith since the date hereof.

All trademarks, logos and brand names used in this presentation are the property of their respective owners.

THANK YOU



Alain Van Loo
Chief Operating Officer
avanloo@intrommune.com
(+1) 917-916-3171